Financière de Tubize SAの1年間の目標
Financière de Tubize SAの1年間の目標は何ですか。
Financière de Tubize SAの1年間の目標は€77 -40.40%です。
1年間の目標の定義は何ですか。
1年目標は今から1年後の予測株価です。
One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.
EURONEXTのセクタHealth Careにおける1年間の目標の企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似の1年間の目標
- McGrath Rentcorpの1年間の目標は$77 -25.85%です。
- RB Global Incの1年間の目標は$77 -9.40%です。
- Advanced Drainage Systems Incの1年間の目標は$77 -46.32%です。
- Stantecの1年間の目標はCAD$77 -26.77%です。
- Discover Servicesの1年間の目標は$77 -40.20%です。
- Agree Realtyの1年間の目標は$77 +1.32%です。
- Financière de Tubize SAの1年間の目標は€77 -40.40%です。
- Kingspan plcの1年間の目標は€77 -0.95%です。
- Bayer AGの1年間の目標は€77 +184.73%です。
- Link Real Estate Investment Trustの1年間の目標はHKD$77 +105.79%です。
- Connect Plcの1年間の目標はGBX7,720 +24,723.15%です。
- MJ Hudson plcの1年間の目標はGBX7,725 +58,757.14%です。
- MJ Hudson plcの1年間の目標はGBX7,725 +58,757.14%です。